The global market for Non-Replicating mRNA Vaccine was valued at US$ 1476 million in the year 2024 and is projected to reach a revised size of US$ 2033 million by 2031, growing at a CAGR of 5.4% during the forecast period.

Non-Replicating mRNA Vaccine Market

A Non-Replicating mRNA Vaccine is a vaccine based on messenger RNA (mRNA) technology, characterized by the use of mRNA that does not replicate within the recipient's body. This vaccine delivers mRNA encoding specific antigens (such as proteins on the surface of viruses) to human cells, prompting them to produce protein fragments of these antigens. This, in turn, stimulates the immune system to generate an immune response against these antigens, such as antibody production and T-cell activation. Due to its non-replicating nature, the vaccine is highly safe and does not cause infection or disease. Non-Replicating mRNA Vaccines have been widely used in the COVID-19 pandemic, demonstrating their advantages of rapid development, efficient production, and easy distribution.

North American market for Non-Replicating mRNA Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Non-Replicating mRNA Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Non-Replicating mRNA Vaccine include Pfizer, Moderna, Curevac, GSK, BioNTech, CSPC, Walvax, Abogen, AIM Vaccine, Sanofi, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Non-Replicating mRNA Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Non-Replicating mRNA Vaccine.

The Non-Replicating mRNA Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Non-Replicating mRNA Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Non-Replicating mRNA Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Non-Replicating mRNA Vaccine Market Report

Report Metric	Details
Report Name	Non-Replicating mRNA Vaccine Market
Accounted market size in year	US$ 1476 million
Forecasted market size in 2031	US$ 2033 million
CAGR	5.4%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	Cancer Non-Replicating mRNA Vaccine Infectious Diseases Non-Replicating mRNA Vaccine Others
Segment by Application	Hospital Clinic CDC Others
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Pfizer, Moderna, Curevac, GSK, BioNTech, CSPC, Walvax, Abogen, AIM Vaccine, Sanofi
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Non-Replicating mRNA Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Non-Replicating mRNA Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

How fast is Non-Replicating mRNA Vaccine Market growing?

Ans: The Non-Replicating mRNA Vaccine Market witnessing a CAGR of 5.4% during the forecast period 2025-2031.

What is the Non-Replicating mRNA Vaccine Market size in 2031?

Ans: The Non-Replicating mRNA Vaccine Market size in 2031 will be US$ 2033 million.

Who are the main players in the Non-Replicating mRNA Vaccine Market report?

Ans: The main players in the Non-Replicating mRNA Vaccine Market are Pfizer, Moderna, Curevac, GSK, BioNTech, CSPC, Walvax, Abogen, AIM Vaccine, Sanofi

What are the Application segmentation covered in the Non-Replicating mRNA Vaccine Market report?

Ans: The Applications covered in the Non-Replicating mRNA Vaccine Market report are Hospital, Clinic, CDC, Others

What are the Type segmentation covered in the Non-Replicating mRNA Vaccine Market report?

Ans: The Types covered in the Non-Replicating mRNA Vaccine Market report are Cancer Non-Replicating mRNA Vaccine, Infectious Diseases Non-Replicating mRNA Vaccine, Others

1 Non-Replicating mRNA Vaccine Market Overview

1.1 Product Definition

1.2 Non-Replicating mRNA Vaccine by Type

1.2.1 Global Non-Replicating mRNA Vaccine Market Value Comparison by Type (2024 VS 2031)

1.2.2 Cancer Non-Replicating mRNA Vaccine

1.2.3 Infectious Diseases Non-Replicating mRNA Vaccine

1.2.4 Others

1.3 Non-Replicating mRNA Vaccine by Application

1.3.1 Global Non-Replicating mRNA Vaccine Market Value by Application (2024 VS 2031)

1.3.2 Hospital

1.3.3 Clinic

1.3.4 CDC

1.3.5 Others

1.4 Global Non-Replicating mRNA Vaccine Market Size Estimates and Forecasts

1.4.1 Global Non-Replicating mRNA Vaccine Revenue 2020-2031

1.4.2 Global Non-Replicating mRNA Vaccine Sales 2020-2031

1.4.3 Global Non-Replicating mRNA Vaccine Market Average Price (2020-2031)

1.5 Assumptions and Limitations

2 Non-Replicating mRNA Vaccine Market Competition by Manufacturers

2.1 Global Non-Replicating mRNA Vaccine Sales Market Share by Manufacturers (2020-2025)

2.2 Global Non-Replicating mRNA Vaccine Revenue Market Share by Manufacturers (2020-2025)

2.3 Global Non-Replicating mRNA Vaccine Average Price by Manufacturers (2020-2025)

2.4 Global Key Players of Non-Replicating mRNA Vaccine, Industry Ranking, 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Non-Replicating mRNA Vaccine, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Non-Replicating mRNA Vaccine, Product Type & Application

2.7 Global Key Manufacturers of Non-Replicating mRNA Vaccine, Date of Enter into This Industry

2.8 Global Non-Replicating mRNA Vaccine Market Competitive Situation and Trends

2.8.1 Global Non-Replicating mRNA Vaccine Market Concentration Rate

2.8.2 The Global 5 and 10 Largest Non-Replicating mRNA Vaccine Players Market Share by Revenue

2.8.3 Global Non-Replicating mRNA Vaccine Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Non-Replicating mRNA Vaccine Market Scenario by Region

3.1 Global Non-Replicating mRNA Vaccine Market Size by Region: 2020 Versus 2024 Versus 2031

3.2 Global Non-Replicating mRNA Vaccine Sales by Region: 2020-2031

3.2.1 Global Non-Replicating mRNA Vaccine Sales by Region: 2020-2025

3.2.2 Global Non-Replicating mRNA Vaccine Sales by Region: 2026-2031

3.3 Global Non-Replicating mRNA Vaccine Revenue by Region: 2020-2031

3.3.1 Global Non-Replicating mRNA Vaccine Revenue by Region: 2020-2025

3.3.2 Global Non-Replicating mRNA Vaccine Revenue by Region: 2026-2031

3.4 North America Non-Replicating mRNA Vaccine Market Facts & Figures by Country

3.4.1 North America Non-Replicating mRNA Vaccine Market Size by Country: 2020 VS 2024 VS 2031

3.4.2 North America Non-Replicating mRNA Vaccine Sales by Country (2020-2031)

3.4.3 North America Non-Replicating mRNA Vaccine Revenue by Country (2020-2031)

3.4.4 United States

3.4.5 Canada

3.5 Europe Non-Replicating mRNA Vaccine Market Facts & Figures by Country

3.5.1 Europe Non-Replicating mRNA Vaccine Market Size by Country: 2020 VS 2024 VS 2031

3.5.2 Europe Non-Replicating mRNA Vaccine Sales by Country (2020-2031)

3.5.3 Europe Non-Replicating mRNA Vaccine Revenue by Country (2020-2031)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Non-Replicating mRNA Vaccine Market Facts & Figures by Region

3.6.1 Asia Pacific Non-Replicating mRNA Vaccine Market Size by Region: 2020 VS 2024 VS 2031

3.6.2 Asia Pacific Non-Replicating mRNA Vaccine Sales by Region (2020-2031)

3.6.3 Asia Pacific Non-Replicating mRNA Vaccine Revenue by Region (2020-2031)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Southeast Asia

3.7 Latin America Non-Replicating mRNA Vaccine Market Facts & Figures by Country

3.7.1 Latin America Non-Replicating mRNA Vaccine Market Size by Country: 2020 VS 2024 VS 2031

3.7.2 Latin America Non-Replicating mRNA Vaccine Sales by Country (2020-2031)

3.7.3 Latin America Non-Replicating mRNA Vaccine Revenue by Country (2020-2031)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.7.7 Colombia

3.8 Middle East and Africa Non-Replicating mRNA Vaccine Market Facts & Figures by Country

3.8.1 Middle East and Africa Non-Replicating mRNA Vaccine Market Size by Country: 2020 VS 2024 VS 2031

3.8.2 Middle East and Africa Non-Replicating mRNA Vaccine Sales by Country (2020-2031)

3.8.3 Middle East and Africa Non-Replicating mRNA Vaccine Revenue by Country (2020-2031)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global Non-Replicating mRNA Vaccine Sales by Type (2020-2031)

4.1.1 Global Non-Replicating mRNA Vaccine Sales by Type (2020-2025)

4.1.2 Global Non-Replicating mRNA Vaccine Sales by Type (2026-2031)

4.1.3 Global Non-Replicating mRNA Vaccine Sales Market Share by Type (2020-2031)

4.2 Global Non-Replicating mRNA Vaccine Revenue by Type (2020-2031)

4.2.1 Global Non-Replicating mRNA Vaccine Revenue by Type (2020-2025)

4.2.2 Global Non-Replicating mRNA Vaccine Revenue by Type (2026-2031)

4.2.3 Global Non-Replicating mRNA Vaccine Revenue Market Share by Type (2020-2031)

4.3 Global Non-Replicating mRNA Vaccine Price by Type (2020-2031)

5 Segment by Application

5.1 Global Non-Replicating mRNA Vaccine Sales by Application (2020-2031)

5.1.1 Global Non-Replicating mRNA Vaccine Sales by Application (2020-2025)

5.1.2 Global Non-Replicating mRNA Vaccine Sales by Application (2026-2031)

5.1.3 Global Non-Replicating mRNA Vaccine Sales Market Share by Application (2020-2031)

5.2 Global Non-Replicating mRNA Vaccine Revenue by Application (2020-2031)

5.2.1 Global Non-Replicating mRNA Vaccine Revenue by Application (2020-2025)

5.2.2 Global Non-Replicating mRNA Vaccine Revenue by Application (2026-2031)

5.2.3 Global Non-Replicating mRNA Vaccine Revenue Market Share by Application (2020-2031)

5.3 Global Non-Replicating mRNA Vaccine Price by Application (2020-2031)

6 Key Companies Profiled

6.1 Pfizer

6.1.1 Pfizer Company Information

6.1.2 Pfizer Description and Business Overview

6.1.3 Pfizer Non-Replicating mRNA Vaccine Sales, Revenue and Gross Margin (2020-2025)

6.1.4 Pfizer Non-Replicating mRNA Vaccine Product Portfolio

6.1.5 Pfizer Recent Developments/Updates

6.2 Moderna

6.2.1 Moderna Company Information

6.2.2 Moderna Description and Business Overview

6.2.3 Moderna Non-Replicating mRNA Vaccine Sales, Revenue and Gross Margin (2020-2025)

6.2.4 Moderna Non-Replicating mRNA Vaccine Product Portfolio

6.2.5 Moderna Recent Developments/Updates

6.3 Curevac

6.3.1 Curevac Company Information

6.3.2 Curevac Description and Business Overview

6.3.3 Curevac Non-Replicating mRNA Vaccine Sales, Revenue and Gross Margin (2020-2025)

6.3.4 Curevac Non-Replicating mRNA Vaccine Product Portfolio

6.3.5 Curevac Recent Developments/Updates

6.4 GSK

6.4.1 GSK Company Information

6.4.2 GSK Description and Business Overview

6.4.3 GSK Non-Replicating mRNA Vaccine Sales, Revenue and Gross Margin (2020-2025)

6.4.4 GSK Non-Replicating mRNA Vaccine Product Portfolio

6.4.5 GSK Recent Developments/Updates

6.5 BioNTech

6.5.1 BioNTech Company Information

6.5.2 BioNTech Description and Business Overview

6.5.3 BioNTech Non-Replicating mRNA Vaccine Sales, Revenue and Gross Margin (2020-2025)

6.5.4 BioNTech Non-Replicating mRNA Vaccine Product Portfolio

6.5.5 BioNTech Recent Developments/Updates

6.6 CSPC

6.6.1 CSPC Company Information

6.6.2 CSPC Description and Business Overview

6.6.3 CSPC Non-Replicating mRNA Vaccine Sales, Revenue and Gross Margin (2020-2025)

6.6.4 CSPC Non-Replicating mRNA Vaccine Product Portfolio

6.6.5 CSPC Recent Developments/Updates

6.7 Walvax

6.7.1 Walvax Company Information

6.7.2 Walvax Description and Business Overview

6.7.3 Walvax Non-Replicating mRNA Vaccine Sales, Revenue and Gross Margin (2020-2025)

6.7.4 Walvax Non-Replicating mRNA Vaccine Product Portfolio

6.7.5 Walvax Recent Developments/Updates

6.8 Abogen

6.8.1 Abogen Company Information

6.8.2 Abogen Description and Business Overview

6.8.3 Abogen Non-Replicating mRNA Vaccine Sales, Revenue and Gross Margin (2020-2025)

6.8.4 Abogen Non-Replicating mRNA Vaccine Product Portfolio

6.8.5 Abogen Recent Developments/Updates

6.9 AIM Vaccine

6.9.1 AIM Vaccine Company Information

6.9.2 AIM Vaccine Description and Business Overview

6.9.3 AIM Vaccine Non-Replicating mRNA Vaccine Sales, Revenue and Gross Margin (2020-2025)

6.9.4 AIM Vaccine Non-Replicating mRNA Vaccine Product Portfolio

6.9.5 AIM Vaccine Recent Developments/Updates

6.10 Sanofi

6.10.1 Sanofi Company Information

6.10.2 Sanofi Description and Business Overview

6.10.3 Sanofi Non-Replicating mRNA Vaccine Sales, Revenue and Gross Margin (2020-2025)

6.10.4 Sanofi Non-Replicating mRNA Vaccine Product Portfolio

6.10.5 Sanofi Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Non-Replicating mRNA Vaccine Industry Chain Analysis

7.2 Non-Replicating mRNA Vaccine Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Non-Replicating mRNA Vaccine Production Mode & Process Analysis

7.4 Non-Replicating mRNA Vaccine Sales and Marketing

7.4.1 Non-Replicating mRNA Vaccine Sales Channels

7.4.2 Non-Replicating mRNA Vaccine Distributors

7.5 Non-Replicating mRNA Vaccine Customer Analysis

8 Non-Replicating mRNA Vaccine Market Dynamics

8.1 Non-Replicating mRNA Vaccine Industry Trends

8.2 Non-Replicating mRNA Vaccine Market Drivers

8.3 Non-Replicating mRNA Vaccine Market Challenges

8.4 Non-Replicating mRNA Vaccine Market Restraints

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

List of Tables

Table 1. Global Non-Replicating mRNA Vaccine Market Value Comparison by Type (2024 VS 2031) & (US$ Million)

Table 2. Global Non-Replicating mRNA Vaccine Market Value by Application (2024 VS 2031) & (US$ Million)

Table 3. Global Non-Replicating mRNA Vaccine Market Competitive Situation by Manufacturers in 2024

Table 4. Global Non-Replicating mRNA Vaccine Sales (K Units) of Key Manufacturers (2020-2025)

Table 5. Global Non-Replicating mRNA Vaccine Sales Market Share by Manufacturers (2020-2025)

Table 6. Global Non-Replicating mRNA Vaccine Revenue (US$ Million) by Manufacturers (2020-2025)

Table 7. Global Non-Replicating mRNA Vaccine Revenue Share by Manufacturers (2020-2025)

Table 8. Global Market Non-Replicating mRNA Vaccine Average Price (US$/Unit) of Key Manufacturers (2020-2025)

Table 9. Global Key Players of Non-Replicating mRNA Vaccine, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Non-Replicating mRNA Vaccine, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Non-Replicating mRNA Vaccine, Product Type & Application

Table 12. Global Key Manufacturers of Non-Replicating mRNA Vaccine, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Non-Replicating mRNA Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-Replicating mRNA Vaccine as of 2024)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Non-Replicating mRNA Vaccine Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 17. Global Non-Replicating mRNA Vaccine Sales by Region (2020-2025) & (K Units)

Table 18. Global Non-Replicating mRNA Vaccine Sales Market Share by Region (2020-2025)

Table 19. Global Non-Replicating mRNA Vaccine Sales by Region (2026-2031) & (K Units)

Table 20. Global Non-Replicating mRNA Vaccine Sales Market Share by Region (2026-2031)

Table 21. Global Non-Replicating mRNA Vaccine Revenue by Region (2020-2025) & (US$ Million)

Table 22. Global Non-Replicating mRNA Vaccine Revenue Market Share by Region (2020-2025)

Table 23. Global Non-Replicating mRNA Vaccine Revenue by Region (2026-2031) & (US$ Million)

Table 24. Global Non-Replicating mRNA Vaccine Revenue Market Share by Region (2026-2031)

Table 25. North America Non-Replicating mRNA Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 26. North America Non-Replicating mRNA Vaccine Sales by Country (2020-2025) & (K Units)

Table 27. North America Non-Replicating mRNA Vaccine Sales by Country (2026-2031) & (K Units)

Table 28. North America Non-Replicating mRNA Vaccine Revenue by Country (2020-2025) & (US$ Million)

Table 29. North America Non-Replicating mRNA Vaccine Revenue by Country (2026-2031) & (US$ Million)

Table 30. Europe Non-Replicating mRNA Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 31. Europe Non-Replicating mRNA Vaccine Sales by Country (2020-2025) & (K Units)

Table 32. Europe Non-Replicating mRNA Vaccine Sales by Country (2026-2031) & (K Units)

Table 33. Europe Non-Replicating mRNA Vaccine Revenue by Country (2020-2025) & (US$ Million)

Table 34. Europe Non-Replicating mRNA Vaccine Revenue by Country (2026-2031) & (US$ Million)

Table 35. Asia Pacific Non-Replicating mRNA Vaccine Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 36. Asia Pacific Non-Replicating mRNA Vaccine Sales by Region (2020-2025) & (K Units)

Table 37. Asia Pacific Non-Replicating mRNA Vaccine Sales by Region (2026-2031) & (K Units)

Table 38. Asia Pacific Non-Replicating mRNA Vaccine Revenue by Region (2020-2025) & (US$ Million)

Table 39. Asia Pacific Non-Replicating mRNA Vaccine Revenue by Region (2026-2031) & (US$ Million)

Table 40. Latin America Non-Replicating mRNA Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 41. Latin America Non-Replicating mRNA Vaccine Sales by Country (2020-2025) & (K Units)

Table 42. Latin America Non-Replicating mRNA Vaccine Sales by Country (2026-2031) & (K Units)

Table 43. Latin America Non-Replicating mRNA Vaccine Revenue by Country (2020-2025) & (US$ Million)

Table 44. Latin America Non-Replicating mRNA Vaccine Revenue by Country (2026-2031) & (US$ Million)

Table 45. Middle East and Africa Non-Replicating mRNA Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 46. Middle East and Africa Non-Replicating mRNA Vaccine Sales by Country (2020-2025) & (K Units)

Table 47. Middle East and Africa Non-Replicating mRNA Vaccine Sales by Country (2026-2031) & (K Units)

Table 48. Middle East and Africa Non-Replicating mRNA Vaccine Revenue by Country (2020-2025) & (US$ Million)

Table 49. Middle East and Africa Non-Replicating mRNA Vaccine Revenue by Country (2026-2031) & (US$ Million)

Table 50. Global Non-Replicating mRNA Vaccine Sales (K Units) by Type (2020-2025)

Table 51. Global Non-Replicating mRNA Vaccine Sales (K Units) by Type (2026-2031)

Table 52. Global Non-Replicating mRNA Vaccine Sales Market Share by Type (2020-2025)

Table 53. Global Non-Replicating mRNA Vaccine Sales Market Share by Type (2026-2031)

Table 54. Global Non-Replicating mRNA Vaccine Revenue (US$ Million) by Type (2020-2025)

Table 55. Global Non-Replicating mRNA Vaccine Revenue (US$ Million) by Type (2026-2031)

Table 56. Global Non-Replicating mRNA Vaccine Revenue Market Share by Type (2020-2025)

Table 57. Global Non-Replicating mRNA Vaccine Revenue Market Share by Type (2026-2031)

Table 58. Global Non-Replicating mRNA Vaccine Price (US$/Unit) by Type (2020-2025)

Table 59. Global Non-Replicating mRNA Vaccine Price (US$/Unit) by Type (2026-2031)

Table 60. Global Non-Replicating mRNA Vaccine Sales (K Units) by Application (2020-2025)

Table 61. Global Non-Replicating mRNA Vaccine Sales (K Units) by Application (2026-2031)

Table 62. Global Non-Replicating mRNA Vaccine Sales Market Share by Application (2020-2025)

Table 63. Global Non-Replicating mRNA Vaccine Sales Market Share by Application (2026-2031)

Table 64. Global Non-Replicating mRNA Vaccine Revenue (US$ Million) by Application (2020-2025)

Table 65. Global Non-Replicating mRNA Vaccine Revenue (US$ Million) by Application (2026-2031)

Table 66. Global Non-Replicating mRNA Vaccine Revenue Market Share by Application (2020-2025)

Table 67. Global Non-Replicating mRNA Vaccine Revenue Market Share by Application (2026-2031)

Table 68. Global Non-Replicating mRNA Vaccine Price (US$/Unit) by Application (2020-2025)

Table 69. Global Non-Replicating mRNA Vaccine Price (US$/Unit) by Application (2026-2031)

Table 70. Pfizer Company Information

Table 71. Pfizer Description and Business Overview

Table 72. Pfizer Non-Replicating mRNA Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 73. Pfizer Non-Replicating mRNA Vaccine Product

Table 74. Pfizer Recent Developments/Updates

Table 75. Moderna Company Information

Table 76. Moderna Description and Business Overview

Table 77. Moderna Non-Replicating mRNA Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 78. Moderna Non-Replicating mRNA Vaccine Product

Table 79. Moderna Recent Developments/Updates

Table 80. Curevac Company Information

Table 81. Curevac Description and Business Overview

Table 82. Curevac Non-Replicating mRNA Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 83. Curevac Non-Replicating mRNA Vaccine Product

Table 84. Curevac Recent Developments/Updates

Table 85. GSK Company Information

Table 86. GSK Description and Business Overview

Table 87. GSK Non-Replicating mRNA Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 88. GSK Non-Replicating mRNA Vaccine Product

Table 89. GSK Recent Developments/Updates

Table 90. BioNTech Company Information

Table 91. BioNTech Description and Business Overview

Table 92. BioNTech Non-Replicating mRNA Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 93. BioNTech Non-Replicating mRNA Vaccine Product

Table 94. BioNTech Recent Developments/Updates

Table 95. CSPC Company Information

Table 96. CSPC Description and Business Overview

Table 97. CSPC Non-Replicating mRNA Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 98. CSPC Non-Replicating mRNA Vaccine Product

Table 99. CSPC Recent Developments/Updates

Table 100. Walvax Company Information

Table 101. Walvax Description and Business Overview

Table 102. Walvax Non-Replicating mRNA Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 103. Walvax Non-Replicating mRNA Vaccine Product

Table 104. Walvax Recent Developments/Updates

Table 105. Abogen Company Information

Table 106. Abogen Description and Business Overview

Table 107. Abogen Non-Replicating mRNA Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 108. Abogen Non-Replicating mRNA Vaccine Product

Table 109. Abogen Recent Developments/Updates

Table 110. AIM Vaccine Company Information

Table 111. AIM Vaccine Description and Business Overview

Table 112. AIM Vaccine Non-Replicating mRNA Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 113. AIM Vaccine Non-Replicating mRNA Vaccine Product

Table 114. AIM Vaccine Recent Developments/Updates

Table 115. Sanofi Company Information

Table 116. Sanofi Description and Business Overview

Table 117. Sanofi Non-Replicating mRNA Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 118. Sanofi Non-Replicating mRNA Vaccine Product

Table 119. Sanofi Recent Developments/Updates

Table 120. Key Raw Materials Lists

Table 121. Raw Materials Key Suppliers Lists

Table 122. Non-Replicating mRNA Vaccine Distributors List

Table 123. Non-Replicating mRNA Vaccine Customers List

Table 124. Non-Replicating mRNA Vaccine Market Trends

Table 125. Non-Replicating mRNA Vaccine Market Drivers

Table 126. Non-Replicating mRNA Vaccine Market Challenges

Table 127. Non-Replicating mRNA Vaccine Market Restraints

Table 128. Research Programs/Design for This Report

Table 129. Key Data Information from Secondary Sources

Table 130. Key Data Information from Primary Sources

Table 131. Authors List of This Report

List of Figures

Figure 1. Product Picture of Non-Replicating mRNA Vaccine

Figure 2. Global Non-Replicating mRNA Vaccine Market Value Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Non-Replicating mRNA Vaccine Market Share by Type: 2024 & 2031

Figure 4. Cancer Non-Replicating mRNA Vaccine Product Picture

Figure 5. Infectious Diseases Non-Replicating mRNA Vaccine Product Picture

Figure 6. Others Product Picture

Figure 7. Global Non-Replicating mRNA Vaccine Market Value by Application (2020-2031) & (US$ Million)

Figure 8. Global Non-Replicating mRNA Vaccine Market Share by Application: 2024 & 2031

Figure 9. Hospital

Figure 10. Clinic

Figure 11. CDC

Figure 12. Others

Figure 13. Global Non-Replicating mRNA Vaccine Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 14. Global Non-Replicating mRNA Vaccine Market Size (2020-2031) & (US$ Million)

Figure 15. Global Non-Replicating mRNA Vaccine Sales (2020-2031) & (K Units)

Figure 16. Global Non-Replicating mRNA Vaccine Average Price (US$/Unit) & (2020-2031)

Figure 17. Non-Replicating mRNA Vaccine Report Years Considered

Figure 18. Non-Replicating mRNA Vaccine Sales Share by Manufacturers in 2024

Figure 19. Global Non-Replicating mRNA Vaccine Revenue Share by Manufacturers in 2024

Figure 20. Global 5 and 10 Largest Non-Replicating mRNA Vaccine Players: Market Share by Revenue in Non-Replicating mRNA Vaccine in 2024

Figure 21. Non-Replicating mRNA Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 22. Global Non-Replicating mRNA Vaccine Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Figure 23. North America Non-Replicating mRNA Vaccine Sales Market Share by Country (2020-2031)

Figure 24. North America Non-Replicating mRNA Vaccine Revenue Market Share by Country (2020-2031)

Figure 25. United States Non-Replicating mRNA Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 26. Canada Non-Replicating mRNA Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 27. Europe Non-Replicating mRNA Vaccine Sales Market Share by Country (2020-2031)

Figure 28. Europe Non-Replicating mRNA Vaccine Revenue Market Share by Country (2020-2031)

Figure 29. Germany Non-Replicating mRNA Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 30. France Non-Replicating mRNA Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 31. U.K. Non-Replicating mRNA Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 32. Italy Non-Replicating mRNA Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 33. Russia Non-Replicating mRNA Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 34. Asia Pacific Non-Replicating mRNA Vaccine Sales Market Share by Region (2020-2031)

Figure 35. Asia Pacific Non-Replicating mRNA Vaccine Revenue Market Share by Region (2020-2031)

Figure 36. China Non-Replicating mRNA Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 37. Japan Non-Replicating mRNA Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 38. South Korea Non-Replicating mRNA Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 39. India Non-Replicating mRNA Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 40. Australia Non-Replicating mRNA Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 41. China Taiwan Non-Replicating mRNA Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 42. Southeast Asia Non-Replicating mRNA Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 43. Latin America Non-Replicating mRNA Vaccine Sales Market Share by Country (2020-2031)

Figure 44. Latin America Non-Replicating mRNA Vaccine Revenue Market Share by Country (2020-2031)

Figure 45. Mexico Non-Replicating mRNA Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 46. Brazil Non-Replicating mRNA Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 47. Argentina Non-Replicating mRNA Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 48. Colombia Non-Replicating mRNA Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 49. Middle East and Africa Non-Replicating mRNA Vaccine Sales Market Share by Country (2020-2031)

Figure 50. Middle East and Africa Non-Replicating mRNA Vaccine Revenue Market Share by Country (2020-2031)

Figure 51. Turkey Non-Replicating mRNA Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 52. Saudi Arabia Non-Replicating mRNA Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 53. UAE Non-Replicating mRNA Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 54. Global Sales Market Share of Non-Replicating mRNA Vaccine by Type (2020-2031)

Figure 55. Global Revenue Market Share of Non-Replicating mRNA Vaccine by Type (2020-2031)

Figure 56. Global Non-Replicating mRNA Vaccine Price (US$/Unit) by Type (2020-2031)

Figure 57. Global Sales Market Share of Non-Replicating mRNA Vaccine by Application (2020-2031)

Figure 58. Global Revenue Market Share of Non-Replicating mRNA Vaccine by Application (2020-2031)

Figure 59. Global Non-Replicating mRNA Vaccine Price (US$/Unit) by Application (2020-2031)

Figure 60. Non-Replicating mRNA Vaccine Value Chain

Figure 61. Channels of Distribution (Direct Vs Distribution)

Figure 62. Bottom-up and Top-down Approaches for This Report

Figure 63. Data Triangulation

Figure 64. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global mRNA Vaccine Raw Materials Market Research Report 2024

Global mRNA Vaccines Therapeutics Market Research Report 2024

mRNA COVID 19 Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global mRNA Vaccines for Animals Market Research Report 2025

Global Veterinary mRNA Vaccines Market Research Report 2025

Global mRNA Vaccine And Therapeutics Market Insights Forecast to 2030

Global Livestock mRNA Vaccines Market Research Report 2025

mRNA Vaccines Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global mRNA Cancer Vaccines and Therapeutics Market Insights Forecast to 2030

Global mRNA Therapy Market Research Report 2024

mRNA Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global RNA Vaccines Market Insights Forecast to 2030

Global Personalized mRNA Cancer Vaccine Therapy Market Research Report 2025

Global mRNA Delivery System Market Research Report 2024

COVID 19 RNA Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global RSV mRNA Vaccine Market Research Report 2025

Global Nucleic Vaccine Market Insights Forecast to 2030

Vaccine Include COVID 19 Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Self Amplifying RNA Vaccine Market Research Report 2025

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions